Korro Bio

Korro Bio, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, founded in 2018. The company specializes in discovering, developing, and commercializing genetic medicines using its proprietary RNA editing technology, known as Oligonucleotide Promoted Editing of RNA (OPERA®). Korro Bio aims to enhance the lives of patients with serious diseases by making precise edits to RNA, which can help repair proteins affected by genetic mutations. The company's lead product candidate, KRRO-110, is currently in preclinical trials for treating Alpha-1 Antitrypsin Deficiency (AATD). Additionally, Korro Bio is developing programs targeting various conditions, including Parkinson's Disease, Amyotrophic Lateral Sclerosis (ALS), Severe Alcohol-Associated Hepatitis, and subsets of pain. Their CHORD technology allows for highly precise RNA edits, minimizing off-target effects and facilitating effective treatment options.